MedTrace Logo

Observational Study on Second Line Treatment of Liver Metastases With DEBIRI and Cetuximab

NCT01891552 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2015-05-13

No results posted yet for this study

Summary

* The recently introduced chemoembolization has been considered to be a very attractive new method in terms of response in the treatment of liver metastases from colon cancer carcinoma (LM-CRC). It appears to be particularly useful if carried out with the new embolization materials.
* An 80% response rate was reported using TACE with Irinotecan pre-loaded Beads in patients with liver metastases from colon cancer, who had been pretreated with 2 or more lines of chemotherapy.
* Since a greater activity was attained by a combination of Cetuximab and Irinotecan versus Cetuximab in monotherapy, the European Agency for the Evaluation of Medicinal Products (EMEA) has granted authorization to the use of Cetuximab in association with irinotecan in the treatment of irinotecan-refractory CRC-LM.
* In this study we want to collect data on on time to progression and tolerability using DEBIRI+Cetuximab in LM-CRC

Conditions

  • Colon Cancer Liver Metastasis

Sponsors & Collaborators

  • International Group of Endovascular Oncology

    lead OTHER

Principal Investigators

  • GIAMMARIA FIORENTINI, MD · International Group of Endovascular Oncology

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2015-05-31
Completion
2015-05-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01891552 on ClinicalTrials.gov